Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Agulnik

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Therapeutic Targets|January 18, 2007
Malignancies of the head and neck: the role for molecular targeted agentsMark Agulnik
Medical Oncology (Northwood, London, England)|January 19, 2012
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)Mark Agulnik
Cancer|August 13, 2011
New developments in mammalian target of rapamycin inhibitors for the treatment of sarcomaMark Agulnik
Drugs|February 27, 2013
Promising new molecular targeted therapies in head and neck cancerKelly Dorsey, Mark Agulnik
Current Treatment Options in Oncology|March 17, 2018
Epithelioid Hemangioendothelioma: Update on Diagnosis and TreatmentAri Rosenberg, Mark Agulnik
Targeted Oncology|June 23, 2018
Growing Role of Regorafenib in the Treatment of Patients with SarcomaMark Agulnik, Steven Attia
Expert Opinion on Therapeutic Targets|January 23, 2008
Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directionsOlivia Aranha, Mark Agulnik
Expert Opinion on Investigational Drugs|August 21, 2015
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomasNisha Mohindra, Mark Agulnik
Expert Opinion on Investigational Drugs|April 23, 2011
Targeted therapies in bone sarcomas: current approach and future directionsJessica Lee Yarber, Mark Agulnik
Oncotargets and Therapy|March 11, 2014
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinibMitul D Gandhi, Mark Agulnik
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Therapeutic Targets|January 18, 2007
Malignancies of the head and neck: the role for molecular targeted agentsMark Agulnik
Medical Oncology (Northwood, London, England)|January 19, 2012
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN)Mark Agulnik
Cancer|August 13, 2011
New developments in mammalian target of rapamycin inhibitors for the treatment of sarcomaMark Agulnik
Drugs|February 27, 2013
Promising new molecular targeted therapies in head and neck cancerKelly Dorsey, Mark Agulnik
Current Treatment Options in Oncology|March 17, 2018
Epithelioid Hemangioendothelioma: Update on Diagnosis and TreatmentAri Rosenberg, Mark Agulnik
Targeted Oncology|June 23, 2018
Growing Role of Regorafenib in the Treatment of Patients with SarcomaMark Agulnik, Steven Attia
Expert Opinion on Therapeutic Targets|January 23, 2008
Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directionsOlivia Aranha, Mark Agulnik
Expert Opinion on Investigational Drugs|August 21, 2015
Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomasNisha Mohindra, Mark Agulnik
Expert Opinion on Investigational Drugs|April 23, 2011
Targeted therapies in bone sarcomas: current approach and future directionsJessica Lee Yarber, Mark Agulnik
Oncotargets and Therapy|March 11, 2014
Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinibMitul D Gandhi, Mark Agulnik
Pageof 12